Action Odonate Therapeutics - ODT

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

1,12

Prix Achat

1,11

Prix Vente

1,16

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

16,8k

Clôture Veille

1,12

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

15 000

Rendement du Dividende

Ratio Cours sur Bénéfices

0,00

Bénéfice par action (BPA)

488,33

Chiffre d'affairess

Bénéfice net

7,33M

Odonate Therapeutics Inc is a Shell company. Odonate Therapeutics Inc is a Shell company.

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Siège social

Carson City, Nevada, USA

Fondé

Odonate Announces Expected Delisting of Its Stock

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC...

Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to...

Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and nine months ended September 30, 2021. As of...

SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm

SAN DIEGO, Sept. 08, 2021 (GLOBE NEWSWIRE) -- National law firm Morris Kandinov is investigating the actions...

Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021...

Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021

Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced...

Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel

Following feedback from the U.S. Food and Drug Administration (FDA) in a pre-New Drug Application meeting, Odonate Therapeutics, Inc. (NASDAQ:...

Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and...

Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 S...

CONTESSA Achieved Primary Endpoint – Tesetaxel Plus a Reduced Dose of Capecitabine Significantly Improved Progression-free Survival (PFS) Versus...

Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast...

Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

ODT - Frequently Asked Questions (FAQ)

What is the current Odonate Therapeutics share price?

The current share price of Odonate Therapeutics is US$ 1,12

How many Odonate Therapeutics shares are in issue?

Odonate Therapeutics has 15 000 shares in issue

What is the market cap of Odonate Therapeutics?

The market capitalisation of Odonate Therapeutics is USD 16,8k

What is the 1 year trading range for Odonate Therapeutics share price?

Odonate Therapeutics has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the reporting currency for Odonate Therapeutics?

Odonate Therapeutics reports financial results in USD

What is the latest annual profit for Odonate Therapeutics?

The latest annual profit of Odonate Therapeutics is USD 7,33M

What is the registered address of Odonate Therapeutics?

The registered address for Odonate Therapeutics is 112 NORTH CURRY STREET, CARSON CITY, NEVADA

Which industry sector does Odonate Therapeutics operate in?

Odonate Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
RGCRegencell Bioscience Holdings Ltd	US$ 14,25 (239,29%)	23,32M
LZMHLZ Technology Holdings Ltd	US$ 13,29 (62,47%)	860,58k
HMRHeidmar Maritime Holdings Corporation	US$ 4,08 (60,00%)	84,62M
ICONIcon Energy Corporation	US$ 0,1356 (45,65%)	85,42M
AVAHAveanna Healthcare Holdings Inc	US$ 5,15 (37,70%)	3,4M
CMCTCreative Media and Community Trust Corporation	US$ 0,35 (-46,15%)	2,1M
SPHLSpringview Holdings Ltd	US$ 0,7194 (-41,98%)	2,7M
ADTXAditxt Inc	US$ 0,0339 (-40,32%)	118,62M
ULYUrgent ly Inc	US$ 0,3086 (-39,44%)	1,76M
PSTVPlus Therapeutics Inc	US$ 0,7501 (-38,01%)	3,88M
SPGCSacks Parente Golf Inc	US$ 0,1388 (28,52%)	365,71M
NVDANVIDIA Corporation	US$ 115,58 (-0,14%)	298,49M
INTCIntel Corporation	US$ 23,70 (14,60%)	243,19M
TSLLDirexion Daily TSLA Bull 2X Trust ETF	US$ 8,585 (-6,07%)	217,39M
TQQQProShares UltraPro QQQ	US$ 57,79 (-5,46%)	121,12M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Odonate Therapeutics Inc (ODT)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Odonate Therapeutics Inc

ODT Dernières nouvelles

Odonate Announces Expected Delisting of Its Stock

Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm

Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021

Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021

Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel

Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020

Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 S...

Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast...

ODT - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Odonate Therapeutics Inc (ODT) Cours

Odonate Therapeutics Inc (ODT)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Odonate Therapeutics Inc

ODT Dernières nouvelles

Odonate Announces Expected Delisting of Its Stock

Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

SHAREHOLDER ALERT: Morris Kandinov Investigating ODT, AYTU, EAR, and CORT; Shareholders are Encouraged to Contact the Firm

Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021

Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021

Odonate Therapeutics Announces Discontinuation of Development of Tesetaxel

Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020

Positive Results of CONTESSA, a Phase 3 Study of Tesetaxel in Patients with Metastatic Breast Cancer, Presented at the 2020 S...

Odonate Therapeutics Initiates Cohort 3 of CONTESSA TRIO to Evaluate Tesetaxel Monotherapy in Patients with Metastatic Breast...

ODT - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS